Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -31952.78% is 2190% below its 5-year average of -1395.57%, near the high end of its 5-year range (-138966.63%–100.00%).
37.61% below its 12-month average of -23220.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
-31952.78%
GROSS MARGIN AVG TTM
-23220.00%
GROSS MARGIN AVG 3Y
-6243.93%
GROSS MARGIN AVG 5Y
-1395.57%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-37.61%
CURRENT VS 3Y AVG
-411.74%
CURRENT VS 5Y AVG
-2189.58%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-77317.93%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$213.71M
Gross Margin
-31952.78%
TTM Avg
-23220.00%
3Y Avg
-6243.93%
5Y Avg
-1395.57%
Market Cap
$214.19M
Gross Margin
87.24%
TTM Avg
79.57%
3Y Avg
65.64%
5Y Avg
63.99%
Market Cap
$214.64M
Gross Margin
85.91%
TTM Avg
92.95%
3Y Avg
46.48%
5Y Avg
30.98%
Market Cap
$215.04M
Gross Margin
64.24%
TTM Avg
63.06%
3Y Avg
61.57%
5Y Avg
61.22%
Market Cap
$209.77M
Gross Margin
83.89%
TTM Avg
91.94%
3Y Avg
70.97%
5Y Avg
47.31%
Market Cap
$206.66M
Gross Margin
89.36%
TTM Avg
-9.34%
3Y Avg
-63.64%
5Y Avg
-318.96%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $213.71M | -31952.78% | -23220.00% | -6243.93% | -1395.57% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.19M | 87.24% | 79.57% | 65.64% | 63.99% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | 85.91% | 92.95% | 46.48% | 30.98% |
| Niagen Bioscience Inc (NAGE)vs › | $215.04M | 64.24% | 63.06% | 61.57% | 61.22% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 86.89% | 79.42% | 84.96% | 87.58% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.77M | 83.89% | 91.94% | 70.97% | 47.31% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.82M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.99M | 31.38% | 30.34% | 28.84% | 29.64% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.66M | 89.36% | -9.34% | -63.64% | -318.96% |
| Sionna Therapeutics, Inc. (SION)vs › | $205.89M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
-31952.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -116500.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | -38800.00% |
| 2023-09-30 | -20316.00% |
| 2023-06-30 | -16711.11% |
| 2023-03-31 | -7633.85% |
| 2022-12-31 | 90.51% |
| 2022-09-30 | -138966.63% |
| 2022-06-30 | 89.56% |
| 2022-03-31 | -618.44% |
| 2021-12-31 | -41.39% |
| 2021-09-30 | 100.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | -22.62% |
| 2020-12-31 | 100.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
